Myriad Genetics, Inc. (MYGN)

Myriad Genetics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	824.5	837.6	753.2	678.4	690.6
Revenue Growth (YoY)	-1.56%	11.21%	11.03%	-1.77%	23.96%
Cost of Revenue	247.9	252.2	236.2	202	197.6
Gross Profit	576.6	585.4	517	476.4	493
Selling, General & Admin	536.8	560	572.9	514.7	537.8
Research & Development	106.8	113.4	88.7	85.4	81.9
Other Operating Expenses	319.4	35.5	112.8	16.9	63.8
Total Operating Expenses	963	708.9	774.4	617	683.5
Operating Income	-387.2	-123.5	-257.4	-140.6	-190.5
Interest Income	1.8	1.7	2.5	2.6	0.7
Interest Expense	-10.5	-7.8	-2.9	-3.2	-6.6
Other Non-Operating Income (Expense)	0.8	1.1	-4.4	0.6	139.3
Total Non-Operating Income (Expense)	-7.9	-5	-4.8	0	133.4
Pretax Income	-395.1	-123.5	-262.2	-140.6	-57.1
Provision for Income Taxes	-29.2	3.8	1.1	-28.6	-29.9
Net Income	-365.9	-127.3	-263.3	-112	-27.2
Net Income to Common	-365.9	-127.3	-263.3	-112	-27.2
Shares Outstanding (Basic)	93	91	83	81	78
Shares Outstanding (Diluted)	93	91	83	81	78
Shares Change (YoY)	2.21%	9.42%	2.73%	3.33%	4.28%
EPS (Basic)	-3.95	-1.41	-3.18	-1.39	-0.35
EPS (Diluted)	-3.95	-1.41	-3.18	-1.39	-0.35
Shares Outstanding	93.5	91.3	89.9	81.2	80
Free Cash Flow	-13.8	-27.7	-174.1	-151.6	0.6
Free Cash Flow Per Share	-0.15	-0.31	-2.10	-1.88	0.01
Gross Margin	69.93%	69.89%	68.64%	70.22%	71.39%
Operating Margin	-46.96%	-14.74%	-34.17%	-20.73%	-27.58%
Profit Margin	-44.38%	-15.20%	-34.96%	-16.51%	-3.94%
FCF Margin	-1.67%	-3.31%	-23.11%	-22.35%	0.09%
EBITDA	-333.5	-62.3	-195.5	-87.9	-127.7
EBITDA Margin	-40.45%	-7.44%	-25.96%	-12.96%	-18.49%
EBIT	-387.2	-123.5	-257.4	-140.6	-190.5
EBIT Margin	-46.96%	-14.74%	-34.17%	-20.73%	-27.58%
Effective Tax Rate	7.39%	-3.08%	-0.42%	20.34%	52.36%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q